Arca
Skip to content
Tools
Tools

RPE65: Retinoid isomerohydrolase

Critical isomerohydrolase in the retinoid cycle involved in regeneration of 11-cis-retinal, the chromophore of rod and cone opsins.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on RPE65, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Other 1

Approved1

  • Voretigene neparvovec

Phase 31

  • Emixustat

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      Voretigene neparvovecApprovedSpark TherapeuticsGeneExogenous geneRetinoid isomerohydrolase exogenous gene4
      EmixustatPhase 3Kubota Vision Inc.Small moleculeInhibitorRetinoid isomerohydrolase inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.
      Monitoring and Early Detection of Treatable Inherited RETinal Disease in Children and AdolescentsVoretigene neparvovec—RecruitingUniversity College, LondonOct 28, 2026
      Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)Voretigene neparvovec—Active, not recruitingGenentech, Inc.Jul 27, 2018
      Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2Voretigene neparvovecPhase 1 / Phase 2Active, not recruitingSpark Therapeutics, Inc.Sep 24, 2010
      Safety and Efficacy Study in Subjects With Leber Congenital AmaurosisVoretigene neparvovecPhase 3Active, not recruitingSpark Therapeutics, Inc.Oct 22, 2009

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Leber congenital amaurosis 20.82
      • Leber congenital amaurosis0.77
      • Inherited retinal dystrophy0.69
      • RPE65-related recessive retinopathy0.68
      • Retinitis pigmentosa 87 with choroidal involvement0.65
      • Hereditary disease0.52
      • Autosomal recessive retinitis pigmentosa0.51
      • Stargardt disease0.45
      • Retinal disorder0.42
      • Abnormality of the eye0.41
      • Severe early-childhood-onset retinal dystrophy0.39

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3831182, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q16518, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.